Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting

Ramsey, 2011, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, N Engl J Med, 365, 1663, 10.1056/NEJMoa1105185

Davies, 2013, Efficacy and safety of ivacaftor in patients aged 6 to 11years with cystic fibrosis with a G551D mutation, Am J Respir Crit Care Med, 187, 1219, 10.1164/rccm.201301-0153OC

McKone, 2014, Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST), Lancet Respir Med, 2, 902, 10.1016/S2213-2600(14)70218-8

Davies, 2016, Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study, Lancet Respir Med, 4, 107, 10.1016/S2213-2600(15)00545-7

Sawicki, 2015, Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data, Am J Respir Crit Care Med, 192, 836, 10.1164/rccm.201503-0578OC

Rowe, 2014, Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis, Am J Respir Crit Care Med, 190, 175, 10.1164/rccm.201404-0703OC

Barry, 2014, Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease, Chest, 146, 152, 10.1378/chest.13-2397

Borowitz, 2016, Nutritional status improved in cystic fibrosis patients with the G551D mutation after treatment with ivacaftor, Dig Dis Sci, 61, 198, 10.1007/s10620-015-3834-2

Castro, 2002, Resting energy expenditure in young patients with cystic fibrosis receiving antibiotic therapy for acute respiratory exacerbations, Clin Nutr, 2, 141, 10.1054/clnu.2001.0522

Heltshe, 2015, Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor, Clin Infect Dis, 60, 703, 10.1093/cid/ciu944

Hisert, 2017, Restoring CFTR function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections, Am J Respir Crit Care Med, 195, 1617, 10.1164/rccm.201609-1954OC

Bellin, 2013, Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study, Pediatr Diabetes, 14, 417, 10.1111/pedi.12026

Hayes, 2014, Resolution of cystic fibrosis–related diabetes with ivacaftor therapy, Am J Respir Crit Care Med, 190, 590, 10.1164/rccm.201405-0882LE

Sermet-Gaudelus, 2016, Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation, J Cyst Fibros, 15, e67, 10.1016/j.jcf.2016.09.003